Translation of oncolytic viruses in sarcoma
Sarcomas are a rare and highly diverse group of malignancies of mesenchymal origin. While sarcomas are generally considered resistant to immunotherapy, recent studies indicate subtype-specific differences in clinical response to checkpoint inhibitors (CPIs) that are associated with distinct immune p...
Saved in:
| Main Authors: | Steven I. Robinson, Roya E. Rochell, Velia Penza, Shruthi Naik |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295032992400064X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1
by: Christina Funk, et al.
Published: (2024-03-01) -
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysisResearch in context
by: Poyee Lau, et al.
Published: (2025-08-01) -
Clinical trials on oncolytic viruses
by: I. V. Golovinov, et al.
Published: (2025-01-01) -
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis
by: Jia-Li Zhao, et al.
Published: (2024-11-01) -
Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification
by: Jason M. Tonne, et al.
Published: (2024-09-01)